A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

In this video, David A. Eichenbaum, MD, FASRS, discusses late-stage wet age-related macular degeneration assets presented at the American Academy of Ophthalmology meeting.Eichenbaum noted that ...

Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its chief executive officer, Gregory D. Kunst, will present preclinical data highlighting the ...

Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal ...

Nebraska Medicine helps tens of thousands of patients every year, but one unique facility on campus can’t be found anywhere ...

The clinical trial enrolled 38 adults aged 60 and older who had advanced geographic atrophy, the late stage of macular ...